» Articles » PMID: 32409230

Understanding Novel COVID-19: Its Impact on Organ Failure and Risk Assessment for Diabetic and Cancer Patients

Overview
Date 2020 May 16
PMID 32409230
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

The current pandemic outbreak of COVID-19 originated from Wuhan, China. It is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with significant mortality and morbidity rate. The severe risk factors are commonly detected in patients of older age and with medical comorbidities like cancer and diabetes. Scientists and doctors have scrambled to gain knowledge about the novel virus and its pathophysiology in order to discover possible therapeutic regimens and vaccines for COVID-19. The therapeutic strategies like targeting the viral genome emphasize the promising approach to target COVID-19. Additionally, blocking the receptor, ACE2 via the neutralizing antibodies for viral escape that prevents it from entering into the cells provides another therapeutic regimen. In this review article, we have presented the effect of SARS-CoV-2 infection in comorbid patients and discussed organ failure caused by this virus. Based on the data available from the scientific literature and ongoing clinical trials, we have focused on therapeutic strategies. We hope that we would fill the gaps that puzzled the researchers and clinicians with the best of our knowledge collected for the betterment of the patients for the coming future.

Citing Articles

COVID-19 vaccine acceptance among health care professionals in Ethiopia: A systematic review and meta-analysis.

Moltot T, Lemma T, Silesh M, Sisay M, Shewangizaw A, Getaneh T Hum Vaccin Immunother. 2023; 19(1):2188854.

PMID: 36949629 PMC: 10072108. DOI: 10.1080/21645515.2023.2188854.


Liver injury in COVID-19: Clinical features, potential mechanisms, risk factors and clinical treatments.

Zhao S, Li Y, Li Y, Su C World J Gastroenterol. 2023; 29(2):241-256.

PMID: 36687127 PMC: 9846943. DOI: 10.3748/wjg.v29.i2.241.


Clinical effects of 2-DG drug restraining SARS-CoV-2 infection: A fractional order optimal control study.

Samui P, Mondal J, Ahmad B, Chatterjee A J Biol Phys. 2022; 48(4):415-438.

PMID: 36459249 PMC: 9716179. DOI: 10.1007/s10867-022-09617-9.


Healthcare Workers and Nonhealthcare Workers Pro-Vaccination Attitude and Its Associated Factors towards COVID-19 Vaccine Globally: A Systematic Review and Meta-Analysis.

Wake A Interdiscip Perspect Infect Dis. 2022; 2022:2443785.

PMID: 36262688 PMC: 9576430. DOI: 10.1155/2022/2443785.


COVID-19 Vaccine Acceptance Level in Ethiopia: A Systematic Review and Meta-Analysis.

Sahile A, Gizaw G, Mgutshini T, Gebremariam Z, Bekele G Can J Infect Dis Med Microbiol. 2022; 2022:2313367.

PMID: 36061634 PMC: 9436617. DOI: 10.1155/2022/2313367.


References
1.
Li Y, Bai W, Hashikawa T . The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol. 2020; 92(6):552-555. PMC: 7228394. DOI: 10.1002/jmv.25728. View

2.
Hou C, Chen J, Zhou Y, Hua L, Yuan J, He S . The effectiveness of quarantine of Wuhan city against the Corona Virus Disease 2019 (COVID-19): A well-mixed SEIR model analysis. J Med Virol. 2020; 92(7):841-848. DOI: 10.1002/jmv.25827. View

3.
Wu K, Peng G, Wilken M, Geraghty R, Li F . Mechanisms of host receptor adaptation by severe acute respiratory syndrome coronavirus. J Biol Chem. 2012; 287(12):8904-11. PMC: 3308800. DOI: 10.1074/jbc.M111.325803. View

4.
Wosten-van Asperen R, Lutter R, Specht P, Moll G, VAN Woensel J, van der Loos C . Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin-(1-7) or an angiotensin II receptor antagonist. J Pathol. 2011; 225(4):618-27. DOI: 10.1002/path.2987. View

5.
Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H . Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020; 8(5):475-481. PMC: 7102538. DOI: 10.1016/S2213-2600(20)30079-5. View